Medgenics receives ODD for Infradure Biopump to treat Hepatitis D

Medgenics' Infradure Biopump has received orphan drug designation (ODD) from the FDA's Office of Orphan Products Development for the treatment of Hepatitis D. Infradure is the version of Medgenics' Biopump technology platform, which produces interferon alpha, commonly used to treat hepatitis. This marks the first ODD granted for treatment of a clinical indication using the Biopump, a tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own skin biopsy for the treatment of a range of chronic diseases, including anaemia, hepatitis and haemophilia.

Medgenics' Infradure Biopump has received orphan drug designation (ODD) from the FDA's Office of Orphan Products Development for the treatment of Hepatitis D. Infradure is the version of Medgenics' Biopump technology platform, which produces interferon alpha, commonly used to treat hepatitis. This marks the first ODD granted for treatment of a clinical indication using the Biopump, a tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own skin biopsy for the treatment of a range of chronic diseases, including anaemia, hepatitis and haemophilia.

This article is tagged to:
Sector: Medical Devices
Geography: Israel
×

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.